Aviva
RPRX icon

Aviva’s Royalty Pharma RPRX Stock Holding History

Aviva’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Buy
359,125
+35,302
+11% +$1.84M 0.03% 420
2026
Q1 		$15.5M Buy
323,823
+8,749
+3% +$383K 0.03% 452
2025
Q4 		$12.2M Buy
315,074
+16,741
+6% +$638K 0.02% 511
2025
Q3 		$10.5M Buy
298,333
+17,754
+6% +$643K 0.02% 524
2025
Q2 		$10.1M Buy
280,579
+17,377
+7% +$576K 0.02% 522
2025
Q1 		$8.19M Buy
263,202
+34,133
+15% +$1.08M 0.02% 490
2024
Q4 		$5.84M Buy
229,069
+214,946
+1,522% +$5.7M 0.02% 514
2024
Q3 		$400K Sell
14,123
-48
-0.3% -$1.33K ﹤0.01% 838
2024
Q2 		$374K Hold
14,171
– – ﹤0.01% 864
2024
Q1 		$430K Buy
14,171
+177
+1% +$5.22K ﹤0.01% 887
2023
Q4 		$393K Hold
13,994
– – ﹤0.01% 898
2023
Q3 		$380K Sell
13,994
-53
-0.4% -$1.57K ﹤0.01% 911
2023
Q2 		$432K Sell
14,047
-4,983
-26% -$169K ﹤0.01% 895
2023
Q1 		$686K Sell
19,030
-30,939
-62% -$1.15M ﹤0.01% 904
2022
Q4 		$1.97M Sell
49,969
-1,048
-2% -$43.7K 0.01% 707
2022
Q3 		$2.05M Sell
51,017
-24,109
-32% -$1.03M 0.01% 699
2022
Q2 		$3.16M Sell
75,126
-8,223
-10% -$337K 0.02% 678
2022
Q1 		$3.25M Buy
83,349
+32,894
+65% +$1.29M 0.02% 686
2021
Q4 		$2.01M Sell
50,455
-4,952
-9% -$192K 0.01% 865
2021
Q3 		$2M Sell
55,407
-48,472
-47% -$1.88M 0.01% 752
2021
Q2 		$4.26M Buy
103,879
+1,560
+2% +$66.4K 0.02% 635
2021
Q1 		$4.46M Buy
102,319
+68,469
+202% +$3.25M 0.02% 559
2020
Q4 		$1.69M Buy
+33,850
New +$1.44M 0.01% 719

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aviva's RPRX Position: Q2 2026 in Review

Aviva increased its Royalty Pharma (RPRX) stake by 11% in Q2 2026, buying an estimated $1.84M and bringing the position to 359,125 shares worth $20.1M. The position accounts for 0.03% of the portfolio, ranked #420.

Aviva first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Aviva held 359,125 shares of Royalty Pharma worth $20.1M as of Q2 2026.
  • Aviva bought 35,302 Royalty Pharma shares in Q2 2026, an estimated $1.84M.
  • Royalty Pharma made up 0.03% of Aviva's portfolio in Q2 2026, its #420 holding.
  • Aviva first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.